← All trials
NCT03352310
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 16, 2018
- Primary completion
- Jun 30, 2020
- Completion date
- Dec 30, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Mononuclear Therapeutics Ltd.Lead sponsor
- Chinese University of Hong KongOverall official - principal investigator
- Chinese University of Hong KongCollaborator
- China Spinal Cord Injury NetworkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.